NasdaqCM - Delayed Quote USD

BioVie Inc. (BIVI)

0.4918 -0.0071 (-1.42%)
At close: May 17 at 4:00 PM EDT
0.4800 -0.01 (-2.40%)
After hours: May 17 at 7:12 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Cuong Viet Do M.B.A. President, CEO & Director 1.08M -- 1966
Ms. Joanne Wendy Kim CPA CFO, Treasurer & Corporate Secretary 397.38k -- 1955
Dr. Joseph M. Palumbo M.D. Executive VP of R&D and Chief Medical Officer 722k -- 1960
Mr. Clarence N. Ahlem Senior Vice President of Operations -- -- 1955
Dr. Penelope Markham Ph.D. Senior Vice President of Liver Disease Program -- -- 1966
Ms. Denise Smith Senior Vice President of Manufacturing & Development -- -- --
Dr. Christopher L. Reading Ph.D. Senior Vice President of Alzheimer's Disease Program -- -- 1948
Ms. Sarah Overton Hoit Chief Social Impact Officer -- -- 1968

BioVie Inc.

680 West Nye Lane
Suite 204
Carson City, NV 89703
United States
775 888 3162 https://bioviepharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
18

Description

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Corporate Governance

BioVie Inc.’s ISS Governance QualityScore as of May 1, 2024 is 9. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 5; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 14, 2024 at 8:00 PM UTC - August 19, 2024 at 8:00 PM UTC

BioVie Inc. Earnings Date

Recent Events

May 14, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 19, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 15, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

March 11, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 14, 2024 at 5:40 PM UTC

BioVie Inc at Oppenheimer Healthcare Life Sciences Conference

February 13, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

January 25, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 19, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 29, 2023 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers

AMLX Amylyx Pharmaceuticals, Inc.
1.8300
0.00%
 
ENVB Enveric Biosciences, Inc.
0.8400
-6.67%
 
ACXP Acurx Pharmaceuticals, Inc.
2.2500
+3.21%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.6700
-2.34%
 
PXMD PaxMedica, Inc.
0.2401
-1.50%
 
ATXI Avenue Therapeutics, Inc.
3.7300
+0.81%
 
CERO CERo Therapeutics Holdings, Inc.
1.1000
-0.90%
 
OCEA Ocean Biomedical, Inc.
1.7600
+3.53%
 
PHGE BiomX Inc.
0.3388
+2.64%
 
FBIO Fortress Biotech, Inc.
1.9300
+9.66%